Medicine Matters Oncology

Adding talazoparib to enzalutamide significantly improves the outcomes of untreated patients with metastatic castration-resistant prostate cancer, regardless of homologous recombination repair mutation status, shows the TALAPRO-2 trial.

Adjuvant treatment with osimertinib significantly prolongs overall survival relative to placebo in people with EGFR-mutated, early-stage non-small-cell lung cancer, show trial results.

Preliminary MASAI trial results indicate that AI-supported mammography has a similar rate of breast cancer detection to standard double reading while reducing the screen-reading workload.

An analysis of the CCC19 registry has demonstrated a significant link between receipt of anticancer therapies within 3 months of a COVID-19 diagnosis and an elevated risk for venous thromboembolism